新型糖尿病治疗药物-肠降血糖素类似物依克那肽(Exenatide)  

Exenatide,a novel incretin mimetic hormone for type 2 diabetes

作　　者：阮健 肖志梅[2] 

机构地区：[1]武汉华中科大纳米药业有限公司,武汉430074 [2]湖北省医药工业研究院有限公司,武汉430061

出　　处：《药品评价》2006年第1期65-66,39,共3页Drug Evaluation

摘　　要：依克那肽为一全新类型糖尿病治疗药物,是肠降血糖素类似物。在血糖含量升高的情况下,通过刺激胰高血糖素类肽受体,依克那肽刺激胰岛素分泌,抑制餐后胰高血糖素释放,减缓胃排空速度和养分循环吸收,减少食物摄取。临床研究证实本品能在不引起低血糖和增加体重风险的基础上治疗2型糖尿病,适宜饮食控制和口服其它降糖药物达不到目标血糖水平的患者。Exenatide, a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control. Through stimulation of the glucagonlike peptide receptor, exenatide stimulates the body＇s ability to produce insulin in response to elevated concentrations of blood glucose, inhibits the release of glucagon following meals, slows the rate of gastric emptying and secondarily the rate of nutrient absorption into the bloodstream, and reduces food intake. Clinical studies have demonstrated improved glycemic control with exenatide therapy in patients who are not achieving target glucose levels with diet and oral medications.

关 键 词：依克那肽 药理学 糖尿病 非胰岛索依赖性 药物疗法 

分 类 号：R977.15[医药卫生—药品]